SE0203070D0 - Novel compounds - Google Patents

Novel compounds

Info

Publication number
SE0203070D0
SE0203070D0 SE0203070A SE0203070A SE0203070D0 SE 0203070 D0 SE0203070 D0 SE 0203070D0 SE 0203070 A SE0203070 A SE 0203070A SE 0203070 A SE0203070 A SE 0203070A SE 0203070 D0 SE0203070 D0 SE 0203070D0
Authority
SE
Sweden
Prior art keywords
sup
novel compounds
compounds
pain
therapy
Prior art date
Application number
SE0203070A
Other languages
English (en)
Inventor
Daniel Page
Christopher Walpole
Hua Yang
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0203070A priority Critical patent/SE0203070D0/xx
Publication of SE0203070D0 publication Critical patent/SE0203070D0/xx
Priority to TW092128115A priority patent/TWI285638B/zh
Priority to UAA200502658A priority patent/UA81919C2/uk
Priority to RU2005109156/04A priority patent/RU2323211C2/ru
Priority to ARP030103753A priority patent/AR041626A1/es
Priority to EP03751705A priority patent/EP1554254A1/en
Priority to CNB2003801059214A priority patent/CN100349874C/zh
Priority to JP2004545139A priority patent/JP2006505568A/ja
Priority to MXPA05003901A priority patent/MXPA05003901A/es
Priority to NZ539079A priority patent/NZ539079A/en
Priority to CA002501418A priority patent/CA2501418A1/en
Priority to PL376564A priority patent/PL376564A1/pl
Priority to BR0315320-7A priority patent/BR0315320A/pt
Priority to PCT/SE2003/001604 priority patent/WO2004035548A1/en
Priority to US10/530,499 priority patent/US7407968B2/en
Priority to KR1020057006538A priority patent/KR20050049551A/ko
Priority to AU2003269775A priority patent/AU2003269775B2/en
Priority to ZA200502928A priority patent/ZA200502928B/en
Priority to IS7827A priority patent/IS7827A/is
Priority to NO20052182A priority patent/NO20052182L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/12—Radicals substituted by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE0203070A 2002-10-16 2002-10-16 Novel compounds SE0203070D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
SE0203070A SE0203070D0 (en) 2002-10-16 2002-10-16 Novel compounds
TW092128115A TWI285638B (en) 2002-10-16 2003-10-09 Novel compounds
AU2003269775A AU2003269775B2 (en) 2002-10-16 2003-10-15 Novel compounds
MXPA05003901A MXPA05003901A (es) 2002-10-16 2003-10-15 Nuevos compuestos.
PL376564A PL376564A1 (pl) 2002-10-16 2003-10-15 Nowe związki
ARP030103753A AR041626A1 (es) 2002-10-16 2003-10-15 Compuestos derivados de benzimidazol utilizables para el tratamiento del dolor y de enfermedades.
EP03751705A EP1554254A1 (en) 2002-10-16 2003-10-15 Novel compounds
CNB2003801059214A CN100349874C (zh) 2002-10-16 2003-10-15 新型化合物
JP2004545139A JP2006505568A (ja) 2002-10-16 2003-10-15 新規な化合物
UAA200502658A UA81919C2 (uk) 2002-10-16 2003-10-15 Похідні бензимідазолу, спосіб їх одержання та застосування цих сполук у виробництві різних медикаментів, та фармацевтична композиція, що містить такі сполуки
NZ539079A NZ539079A (en) 2002-10-16 2003-10-15 Cannabinoid receptor ligands useful for the management of pain
CA002501418A CA2501418A1 (en) 2002-10-16 2003-10-15 Novel compounds
RU2005109156/04A RU2323211C2 (ru) 2002-10-16 2003-10-15 Новые производные бензимидазола, способы их получения, их применение и содержащая их фармацевтическая композиция
BR0315320-7A BR0315320A (pt) 2002-10-16 2003-10-15 Composto ou sais farmaceuticamente aceitáveis dos mesmos, uso de um composto, composição farmacêutica, e, métodos para a terapia de dor em um animal de sangue quente e para produzir um composto
PCT/SE2003/001604 WO2004035548A1 (en) 2002-10-16 2003-10-15 Novel compounds
US10/530,499 US7407968B2 (en) 2002-10-16 2003-10-15 Compounds
KR1020057006538A KR20050049551A (ko) 2002-10-16 2003-10-15 신규 화합물
ZA200502928A ZA200502928B (en) 2002-10-16 2005-04-11 Novel compounds.
IS7827A IS7827A (is) 2002-10-16 2005-04-27 Ný efnasambönd
NO20052182A NO20052182L (no) 2002-10-16 2005-05-03 Nye forbindelser

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0203070A SE0203070D0 (en) 2002-10-16 2002-10-16 Novel compounds

Publications (1)

Publication Number Publication Date
SE0203070D0 true SE0203070D0 (en) 2002-10-16

Family

ID=20289294

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0203070A SE0203070D0 (en) 2002-10-16 2002-10-16 Novel compounds

Country Status (20)

Country Link
US (1) US7407968B2 (zh)
EP (1) EP1554254A1 (zh)
JP (1) JP2006505568A (zh)
KR (1) KR20050049551A (zh)
CN (1) CN100349874C (zh)
AR (1) AR041626A1 (zh)
AU (1) AU2003269775B2 (zh)
BR (1) BR0315320A (zh)
CA (1) CA2501418A1 (zh)
IS (1) IS7827A (zh)
MX (1) MXPA05003901A (zh)
NO (1) NO20052182L (zh)
NZ (1) NZ539079A (zh)
PL (1) PL376564A1 (zh)
RU (1) RU2323211C2 (zh)
SE (1) SE0203070D0 (zh)
TW (1) TWI285638B (zh)
UA (1) UA81919C2 (zh)
WO (1) WO2004035548A1 (zh)
ZA (1) ZA200502928B (zh)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
SE0203070D0 (en) 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds
SE0301698D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301701D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0301699D0 (sv) * 2003-06-10 2003-06-10 Astrazeneca Ab Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
ATE417830T1 (de) * 2004-11-02 2009-01-15 Pfizer Sulfonylbenzimidazolderivate
WO2007091950A1 (en) * 2006-02-07 2007-08-16 Astrazeneca Ab Benzimidazoles and imidazopyridines useful in the treatment of diseases or disorders associated with cannabinoid receptor 2 (cb2) such as pain
PT2090570E (pt) 2006-09-05 2011-12-29 Kyowa Hakko Kirin Co Ltd Derivado de imidazole
WO2008032764A1 (fr) * 2006-09-13 2008-03-20 Kyowa Hakko Kirin Co., Ltd. Dérivé hétérocyclique fusionné
NZ582760A (en) 2007-06-21 2011-12-22 Cara Therapeutics Inc Substituted imidazoheterocycles
EP2203171A2 (en) * 2007-08-21 2010-07-07 Merck Sharp & Dohme Corp. Cb2 receptor ligands for the treatment of pain
US8759535B2 (en) 2010-02-18 2014-06-24 High Point Pharmaceuticals, Llc Substituted fused imidazole derivatives, pharmaceutical compositions, and methods of use thereof
ES2899000T3 (es) 2011-07-18 2022-03-09 Merck Patent Gmbh Benzamidas
EP2872138A4 (en) 2012-07-13 2016-04-20 Cleveland Clinic Foundation NEUROPROTECTIVE AGONISTS OF CB2 RECEPTORS
WO2016089648A1 (en) 2014-12-01 2016-06-09 Vtv Therapeutics Llc Bach 1 inhibitors in combination with nrf2 activators and pharmaceutical compositions thereof
CN111658644B (zh) * 2020-03-31 2021-05-14 中山大学 一种小分子stat3抑制剂wz-2-033及其在制备治疗乳腺癌和胃癌药物中的应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2945044A (en) * 1957-07-12 1960-07-12 Ciba Pharm Prod Inc Certain 1-(diethyl-aminoethyl), 5-amino, 2-benzyl or substituted benzyl, benzimidazoles
FR1481049A (fr) * 1965-11-25 1967-05-19 France Ministre Des Armees Nouveaux dialkylaminoalkyl-1 p-alkoxyphényl alkyl-2 benzimidazoles 5-substitués
CA2036307C (en) 1990-03-08 2002-07-09 Susan Jean Ward 3-arylcarbonyl-1-aminoalkyl-1h-indole-containing antiglaucoma compositions and method
FR2741621B1 (fr) * 1995-11-23 1998-02-13 Sanofi Sa Nouveaux derives de pyrazole, procede pour leur preparation et compositions pharmaceutiques en contenant
FR2789079B3 (fr) 1999-02-01 2001-03-02 Sanofi Synthelabo Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant
AUPR118000A0 (en) * 2000-11-02 2000-11-23 Amrad Operations Pty. Limited Therapeutic molecules and methods
DE60237431D1 (de) * 2001-01-29 2010-10-07 Univ Connecticut Rezeptor-selektive cannabimimetische aminoalkylindole
SE0101387D0 (sv) * 2001-04-20 2001-04-20 Astrazeneca Ab Novel compounds
WO2003053938A1 (en) * 2001-12-20 2003-07-03 Novo Nordisk A/S Benzimidazols and indols as glucagon receptor antagonists/inverse agonisten
SE0203070D0 (en) 2002-10-16 2002-10-16 Astrazeneca Ab Novel compounds

Also Published As

Publication number Publication date
AU2003269775B2 (en) 2007-05-03
MXPA05003901A (es) 2005-06-22
PL376564A1 (pl) 2006-01-09
RU2005109156A (ru) 2006-01-20
AR041626A1 (es) 2005-05-26
TWI285638B (en) 2007-08-21
BR0315320A (pt) 2005-08-16
TW200410944A (en) 2004-07-01
KR20050049551A (ko) 2005-05-25
NO20052182L (no) 2005-05-03
US20070105893A1 (en) 2007-05-10
IS7827A (is) 2005-04-27
CN1726194A (zh) 2006-01-25
JP2006505568A (ja) 2006-02-16
RU2323211C2 (ru) 2008-04-27
ZA200502928B (en) 2006-02-22
US7407968B2 (en) 2008-08-05
AU2003269775A1 (en) 2004-05-04
WO2004035548A1 (en) 2004-04-29
EP1554254A1 (en) 2005-07-20
CN100349874C (zh) 2007-11-21
UA81919C2 (uk) 2008-02-25
NZ539079A (en) 2007-11-30
CA2501418A1 (en) 2004-04-29

Similar Documents

Publication Publication Date Title
MY134568A (en) Cb2 receptor agonists
WO2004060882A8 (en) Cb 1/cb 2 receptor ligands and their use in the treatment of pain
HK1079519A1 (en) Furyl compounds
HK1079522A1 (en) Thienyl compounds
DE60045508D1 (de) Dalda-analoge und ihre verwendung
SE0104250D0 (sv) Heterocyclic compounds
SE0203070D0 (en) Novel compounds
SE9802208D0 (sv) Novel compounds
UA86776C2 (ru) Производные бензимидазола, фармацевтическая композиция, которая их содержит, способ их получения и применение
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
TW200504029A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0203303D0 (sv) Novel Compounds
TW200504030A (en) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0203300D0 (sv) Novel Compounds
SE0302570D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
HK1068348A1 (en) Therapeutic heterocycles as bradykinin b2 receptorantagonists
SE0300105D0 (sv) Diarylmethylidene piperdine derivatives, preparations thereof and uses thereof
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SE0203302D0 (sv) Novel Compounds
SE9802209D0 (sv) Novel compounds
SE0400027D0 (sv) Diarylmethyl piperazine derivatives, preparations thereof and uses thereof
SE0203301D0 (sv) Novel Compounds
SE0301445D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0300104D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof
SE0300103D0 (sv) Diarylmethylidene piperidine derivatives, preparations thereof and uses thereof